Navigation Links
Malaria medication may help against 1 type of frontotemporal dementia
Date:2/2/2011

Frontotemporal dementia is caused by a breakdown of nerve cells in the frontal and temporal region of the brain (fronto-temporal lobe), which leads to, among other symptoms, a change in personality and behavior. The cause of some forms of frontotemporal dementia is a genetically determined reduction of a hormone-like growth factor, progranulin. Scientists around Dr. Anja Capell and Prof. Christian Haass have now shown that various drugs that are already on the market to treat malaria, angina pectoris or heart rhythm disturbances can increase the production of progranulin. Accordingly, these drugs are good candidates for treatment of this specific form of frontotemporal dementia. The work will be published in the online edition of the scientific journal Journal of Neuroscience on February 2nd, 2011.

Progranulin is needed in the human brain as a protective factor for sensitive nerve cells, too little progranulin therefore results in a progressive neuronal cell death. As for almost every other gene, there are also two copies of the progranulin gene in the cell. In patients with progranulin dependent frontotemporal dementia, one of the two copies is defective, leading to a 50% reduction in progranulin levels. To rescue the lack of progranulin, the Munich researchers tested various substances for their ability to stimulate the remaining progranulin production and identified a drug called bafilomycin (BafA1). They then examined the molecular mechanism underlying the impact of BafA1 on progranulin more closely. Growth factors such as progranulin are produced in cellular membrane inclusions, known as vesicles. BafA1 has an alkalizing effect on these vesicles: After administration of BafA1 the interior of the vesicles is less acidic and this increases the production of progranulin.

This observation encouraged the researchers to investigate further alkalizing substances for their ability to raise progranulin levels. Among the substances that passed the test were three drugs that are already on the market to treat various diseases: a medication for angina pectoris (bepridil), one for heart rhythm problems (amiodarone) and the widely used malaria drug chloroquine. Chloroquine increased the progranulin level not only in experiments with mouse cells to normal, but also in cells from patients with the defective progranulin gene.

In a clinical study in collaboration with the University of London, the team of Prof. Haass and Dr. Capell will now investigate whether chloroquine actually helps against progranulin dependent frontotemporal dementia. The human studies can be started very soon, as chloroquine has been used on countless patients, so that serious side effects are not to be expected. Even though the Munich scientists are optimistic, Prof. Haass warns against exaggerated hopes. "Experience shows that the step from cell and animal models to the patient is always connected with considerable difficulties. It will take several years until we know, whether chloroquine can be used as therapy for progranulin dependent frontotemporal dementia," says Haass.


'/>"/>

Contact: Katrin Weigmann
katrin.weigmann@dzne.de
49-228-433-02263
Helmholtz Association of German Research Centres
Source:Eurekalert

Related biology news :

1. Malaria modeling and control focus of workshop
2. Malaria-infected cells stiffen, block blood flow
3. New study examines immunity in emerging species of a major mosquito carrer of malaria
4. Researchers link cerebral malaria to epilepsy, behavior disorders
5. UC Riverside cell biologist to investigate how malaria parasite multiplies in red blood cells
6. International malaria research consortium tackles deadly disease
7. Genetic markers offer new clues about how malaria mosquitoes evade eradication
8. Malaria research begins to bite
9. Malarias newest pathway into human cells identified
10. Novartis and collaborators discover novel antimalarial drug candidate
11. New methods, new math speed detection of drug-resistant malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at http://www.nxt-id.com  under "SEC ... . 2016 Year Highlights: Acquisition ...
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
Breaking Biology News(10 mins):
(Date:6/23/2017)... ... June 23, 2017 , ... Biova, LLC., the leader in water soluble egg ... Directors. Dr. Henig will bring a wealth of scientific experience in the food, beverage, ... Technical and Scientific Officer of four major global companies in the last 4 decades. ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Academy of Model ... University Aviation Association (UAA), the unifying voice for collegiate aviation education, are launching ... teamwork, competition, and success through a STEM-based education platform. , Much like the ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... the allergy specialists DST Diagnostische Systeme & Technologien GmbH, thereby expanding its product ... who suffers from hay fever, urticaria, asthma, atopic eczema or a food allergy. ...
(Date:6/22/2017)... ... June 22, 2017 , ... The first human cell line HeLa, established ... first data on cross-contamination of human cell lines with HeLa cells were published. Until ... cell culture labs and is associated with dramatic consequences for research. , In ...
Breaking Biology Technology: